Learn more about the minimally invasive, in-office iTind procedure and how it may enhance BPH patient outcomes.
Learn More 855-930-2712View the "How I Do It: Temporarily Implanted Nitinol Device (iTind)" Case Study
"How I Do It" guide
Managing lower urinary tract symptoms in patients with BPH is a delicate juggling act. Rapid symptom relief is very important, but as more aging patients maintain very active lifestyles, preserving this and sexual function are of growing importance to them.* With the iTind procedure, many patients may not have to compromise. The iTind procedure is a new alternative to medications and their side effects and is a minimally invasive alternative to surgery.
Treatment with the iTind procedure is straightforward and provides rapid symptom relief in the majority of patients.1,2,3 The procedure can be performed in an office or outpatient hospital procedure, under general or local anesthesia. Patients typically return home the same day and often do not require a catheter.1 For patients who prefer a non-pharmaceutical approach to treating their BPH symptoms or are not yet ready for surgery, the iTind procedure is well suited to become a first-line treatment.1
Implantation of the iTind device may cause urinary urgency, pelvic discomfort, dysuria or hematuria. In rare cases, the iTind procedure may cause urinary tract infection or acute urinary retention.
Learn more about the latest option that leaves nothing behind and does not use permanent implants, heat or steam to treat BPH.*
Data provided will be used in accordance with the Olympus Privacy Statement.
The iTind™ device is placed within the prostatic urethra in a folded configuration. Once in place, the iTind device gently expands and its struts exert longitudinal force on the prostatic urethra and the bladder neck at the 12, 5 and 7 o’clock positions.
Over the course of 5 to 7 days, through continuous ischemic pressure and subsequent tissue necrosis and scarring, deep longitudinal channels are created through which urine can flow freely.
The design of the iTind device allows for a straightforward procedure using cystoscopy equipment most urologists already own. Unlike other treatment options, no energy or heat is used to treat the prostate, eliminating the risk of retrograde ejaculation, erectile dysfunction and urinary incontinence.
At post-operative day 5 to 7, the iTind device is completely removed in a second in office procedure. The newly formed channels continue to provide sustained relief over the long-term as demonstrated in clinical testing out to 3 years.1
Implantation of the iTind device may cause urinary urgency, pelvic discomfort, dysuria or hematuria. In rare cases, iTind device may cause urinary tract infection or acute urinary retention.
Insertion
Treatment Period (5-7 Days)
Removal
Dr. Neil Barber
Prof. Francesco Porpiglia
Dr. Enrique RijoHear from urologists sharing their experience with the iTind™ procedure and how they discuss treatment options with their patients. The iTind procedure may not be for everyone. Please consult with a doctor to see if the iTind procedure is right for you.Implantation of the iTind device may cause pelvic discomfort, blood in urine, painful or urgent urination. In rare cases, the iTind device may cause urinary tract infection or a sudden difficulty to urinate.
Dr. Kenneth Kernen
Dr. Naveen KellaDr. Kernen & Dr. Kella are paid consultants to Olympus Corporation of the Americas
The iTind procedure may not be for everyone. Please consult with a doctor to see if the iTind procedure is right for you.
Implantation of the iTind device may cause pelvic discomfort, blood in urine, painful or urgent urination. In rare cases, the iTind device may cause urinary tract infection or a sudden difficulty to urinate.
"How I Do It: Temporarily Implanted Nitinol Device (iTind)" is a case study providing the procedure/technology overview, instruction and techniques used while installing and removing the iTind device.
Data provided will be used in accordance with the Olympus Privacy Statement.
The iTind procedure was developed as a means of minimally invasively treating the symptoms of BPH without the risks associated with surgery, without heating tissue, and without leaving behind a permanent implant.
Clinical data from several peer-reviewed studies have demonstrated that the iTind procedure is effective, well tolerated and preserves sexual function.2 Rapid and significant improvement in lower urinary tract symptoms, flow and quality of life have been observed, and durable improvement for 3 years.1
1. Amparore, Daniele, et al. “3-Year Results Following Treatment with the Second Generation of the Temporary Implantable Nitinol Device in Men with Luts Secondary to Benign Prostatic Obstruction.” Prostate Cancer and Prostatic Diseases, vol. 24, no. 2, 2020, pp. 349–357., https://doi.org/10.1038/s41391-020-00281-5.
2. Chughtai, Bilal, et al. “The ITIND Temporarily Implanted Nitinol Device for the Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia: A Multicenter, Randomized, Controlled Trial.” Urology, vol. 153, 2021, pp. 270–276., doi:10.1016/j.urology.2020.12.022.
3. De Nunzio, C., Cantiello, F., Fiori, C., Crocerossa, F., Tognoni, P., Amparore, D., Baldassarri, V., Elbers, J. R., Sancha, F. G., & Porpiglia, F. (2020). Urinary and sexual function after treatment with temporary implantable nitinol device (itind) in men with luts: 6-month interim results of the MT-06-study. World Journal of Urology, 39(6), 2037–2042. https://doi.org/10.1007/s00345-020-03418-2
Olympus has a dedicated team to assist you with your iTind™ procedure reimbursement related questions.
Field Reimbursement Managers (FRMs)
Olympus has specific Field Reimbursement Manager who can provide reimbursement insight and guidance, as well as a wide range of resources specific to the overall reimbursement process for the iTind procedure.
Olympus UNITE for iTind Helpline
The reimbursement helpline offers the following services:
Olympus UNITE for iTind Patient Access Program
Experienced coding professionals are available to help customers navigate case-specific denials and prior authorizations. Our professionals can assist with documentation, payer communication and provide you with updates on case-specific decisions through a secure and encrypted provider portal. This is an opt-in program for all customers performing the iTind procedure.
Contact Information:
Email: iTindFRM@olympus.com Phone: (877) 205-1533 Hours: 8:30 am - 5:00 pm Eastern Time